Repligen Corporation (NASDAQ:RGEN) Receives $166.43 Average PT from Analysts

Repligen Corporation (NASDAQ:RGEN) has been assigned an average rating of “Buy” from the eighteen brokerages that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and three have issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $166.4286.

A number of equities analysts recently issued reports on the company. Evercore restated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a report on Monday, July 6th. Zacks Research raised Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Roth Capital initiated coverage on Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 price target for the company. Finally, Wells Fargo & Company lifted their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th.

Insider Buying and Selling at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently made changes to their positions in the company. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the 3rd quarter worth approximately $29,000. Bayforest Capital Ltd bought a new stake in Repligen during the fourth quarter worth approximately $32,000. Rachor Investment Advisory Services LLC acquired a new position in Repligen during the fourth quarter valued at approximately $33,000. Los Angeles Capital Management LLC acquired a new position in Repligen during the fourth quarter valued at approximately $36,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Repligen during the second quarter valued at approximately $52,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Price Performance

NASDAQ RGEN opened at $166.83 on Monday. The company has a 50-day moving average price of $142.70 and a two-hundred day moving average price of $131.32. Repligen has a 52 week low of $100.99 and a 52 week high of $175.77. The stock has a market cap of $9.42 billion, a price-to-earnings ratio of 228.53, a price-to-earnings-growth ratio of 3.05 and a beta of 1.03. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts forecast that Repligen will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.